

# **Sun Pharmaceuticals (SA) (Pty) Ltd**

**(Registration Number 2008/025010/07)**

**Annual Financial Statements  
for the year ended 31 March 2018**

---

# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Annual Financial Statements for the year ended 31 March 2018

## Index

---

	<b>PAGE</b>
General Information	2
Directors' Responsibilities and Approval	3
Directors' Report	4
Independent Auditor's Report	5 - 6
Report of the Compiler	7
Statement of Financial Position	8
Statement of Profit or Loss and Other Comprehensive Income	9
Statement of Changes in Equity	10
Accounting Policies	11 - 21
Notes to the Financial Statements	22 - 25

# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Annual Financial Statements for the year ended 31 March 2018

## General Information

---

<b>Country of Incorporation and Domicile</b>	South Africa
<b>Registration Number</b>	2008/025010/07
<b>Nature of Business and Principal Activities</b>	Trade of Pharmaceutical goods and services
<b>Directors</b>	Sudhir Vrundavandas Valia Desmond William Brothers
<b>Registered Office</b>	Ground Floor, West Block, Tugela House Riverside Office Park 1303 Heuwel Avenue, Centurion Gauteng 0157
<b>Business Address</b>	Ground Floor, West Block, Tugela House Riverside Office Park 1303 Heuwel Avenue, Centurion Gauteng 0157
<b>Postal Address</b>	P O Box 10458 Centurion Gauteng 0046
<b>Independent Auditors</b>	Ernst & Young Inc 2052
<b>Company Secretary</b>	Grant Thornton
<b>Independent Compilers</b>	Moollas Financial Solutions Inc

# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Annual Financial Statements for the year ended 31 March 2018

## Directors' Responsibilities and Approval

---

The directors are required by the Companies Act of South Africa to maintain adequate accounting records and are responsible for the content and integrity of the annual financial statements and related financial information included in this report. It is their responsibility to ensure that the annual financial statements satisfy the financial reporting standards as to form and content and present fairly the statement of financial position, results of operations and business of the company, and explain the transactions and financial position of the business of the company at the end of the financial year. The annual financial statements are based upon appropriate accounting policies consistently applied throughout the company and supported by reasonable and prudent judgements and estimates.

The directors acknowledge that they are ultimately responsible for the system of internal financial control established by the company and place considerable importance on maintaining a strong control environment. To enable the directors to meet these responsibilities, the directors sets standards for internal control aimed at reducing the risk of error or loss in a cost effective manner. The standards include the proper delegation of responsibilities within a clearly defined framework, effective accounting procedures and adequate segregation of duties to ensure an acceptable level of risk. These controls are monitored throughout the company and all employees are required to maintain the highest ethical standards in ensuring the company's business is conducted in a manner that in all reasonable circumstances is above reproach.

The focus of risk management in the company is on identifying, assessing, managing and monitoring all known forms of risk across the company. While operating risk cannot be fully eliminated, the company endeavours to minimise it by ensuring that appropriate infrastructure, controls, systems and ethical behaviour are applied and managed within predetermined procedures and constraints.

The directors are of the opinion, based on the information and explanations given by management and the external auditors, that the system of internal control provides reasonable assurance that the financial records may be relied on for the preparation of the annual financial statements. However, any system of internal financial control can provide only reasonable, and not absolute, assurance against material misstatement or loss. The going-concern basis has been adopted in preparing the financial statements. Based on forecasts and available cash resources the directors have no reason to believe that the company will not be a going concern in the foreseeable future. The financial statements support the viability of the company.

The annual financial statements have been audited by the independent auditing firm, Ernst & Young Inc, who have been given unrestricted access to all financial records and related data, including minutes of all meetings of shareholder, the directors and committees of the directors. The directors believe that all representations made to the independent auditor during the audit were valid and appropriate. The external auditors' unqualified audit report is presented on pages 5 to 6.

The annual financial statements as set out on pages 8 to 25 were approved by the directors on 28 June 2018 and were signed on their behalf by:

---

Desmond William Brothers

# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Annual Financial Statements for the year ended 31 March 2018

## Directors' Report

---

The directors present their report for the year ended 31 March 2018.

### 1. Review of activities

#### Main business and operations

The principal activity of the company is trade of pharmaceutical goods and services and there were no major changes herein during the year.

The operating results and statement of financial position of the company are fully set out in the attached financial statements and do not in our opinion require any further comment.

### 2. Going concern

The annual financial statements have been prepared on the basis of accounting policies applicable to a going concern. This basis presumes that funds will be available to finance future operations and that the realisation of assets and settlement of liabilities, contingent obligations and commitments will occur in the ordinary course of business.

### 3. Events after reporting date

The directors are not aware of any matter or circumstance arising since the end of the financial year to the date of this report that could have a material effect on the financial position of the company.

### 4. Authorised and issued share capital

No changes were approved or made to the authorised or issued share capital of the company during the year under review.

### 5. Directors

The directors of the company during the year and to the date of this report are as follows:

Sudhir Vrundavandas Valia

Desmond William Brothers

### 6. Secretary

The company designated secretary is Grant Thornton.

### 7. Independent Auditors

Ernst & Young Inc were the independent auditors for the year under review.



EY  
102 Rivonia Road  
Sandton  
Private Bag 214  
Sandton  
2146

Ernst & Young Incorporated  
Co. Reg. No. 2005/002368/21  
Tel: +27 (0) 11 772 3000  
Fax: +27 (0) 11 772 4000  
Dobex 123 Randburg  
ey.com

## Independent Auditor's Report

To the Shareholders of Sun Pharmaceutical SA (Pty) Ltd

### Report on the Audit of the Financial Statements

#### Opinion

We have audited the financial statements of Sun Pharmaceutical SA (Pty) Ltd set out on pages 8 to 25, which comprise the statement of financial position as at 31 March 2018, and the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the financial statements present fairly, in all material respects, the financial position of Sun Pharmaceutical SA (Pty) Ltd as at 31 March 2018, and its financial performance and cash flows for the year then ended in accordance with International Financial Reporting Standards and the requirements of the Companies Act of South Africa.

#### Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the company in accordance with the Independent Regulatory Board for Auditors *Code of Professional Conduct for Registered Auditors (IRBA Code)*, the International Ethics Standards Board for Accountants *Code of Ethics for Professional Accountants (IESBA code)* and other independence requirements applicable to performing the audit of Sun Pharmaceutical SA (Pty) Ltd. We have fulfilled our other ethical responsibilities in accordance with the IRBA Code, IESBA Code, and in accordance with other ethical requirements applicable to performing the audit of Sun Pharmaceutical SA (Pty) Ltd. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Other Information

The directors are responsible for the other information. The other information comprises the Directors' Report as required by the Companies Act of South Africa. The other information does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express an audit opinion or any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements of our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

#### Responsibilities of the Directors for the financial statements

The directors are responsible for the preparation and fair presentation of the financial statements in accordance with International Financial Reporting Standards and the requirements of the Companies Act of South Africa, and for such internal control as the directors determine is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.



EY  
102 Rivonia Road  
Sandton  
Private Bag X14  
Sandton  
2146

Ernst & Young Inc. (operated)  
Co. Reg. No. 2005/092308/24  
Tel: +27 (0) 11 772 3000  
Fax: +27 (0) 11 772 4000  
Docex 123 Randburg  
ey.com

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

***Auditor's Responsibilities for the Audit of the financial statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Ernst & Young Inc.  
Derek Engelbrecht  
Director  
Registered Auditor  
Chartered Accountant (SA)  
2 July 2018



---

## Report of the Compiler

---

### To the Shareholder of Sun Pharmaceuticals (SA) (Pty) Ltd

We have compiled the accompanying financial statements of Sun Pharmaceuticals (SA) (Pty) Ltd based on information you have provided. These financial statements comprise the statement of financial position of Sun Pharmaceuticals (SA) (Pty) Ltd as at 31 March 2018, the statement of profit or loss and other comprehensive income, the statement of changes in equity for the year then ended, and a summary of significant accounting policies and other explanatory information.

We performed this compilation engagement in accordance with International Standard on Related Services 4410 (Revised), Compilation Engagements.

We have applied our expertise in accounting and financial reporting to assist you in the preparation and presentation of these financial statements in accordance with International Financial Reporting Standards to the financial statements and the requirements of the Companies Act of South Africa. We have complied with relevant ethical requirements, including principles of integrity, objectivity, professional competence and due care.

These financial statements and the accuracy and completeness of the information used to compile them are your responsibility.

Since a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information you provided to us to compile these financial statements. Accordingly, we do not express an audit opinion or a review conclusion on whether these financial statements are prepared in accordance with International Financial Reporting Standards.

**28 June 2018**

---

**Moollas Financial Solutions Inc**

**Muhammad Moola**  
**Chartered Accountant (SA)**

**Building 2, 21 Woodlands Drive**  
**Woodmead Country Club Estate**  
**Woodmead**  
**2052**



# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Financial Statements for the year ended 31 March 2018

## Statement of Financial Position

Figures in R

	Notes	2018	2017
<b>Assets</b>			
<b>Current assets</b>			
Loan to group company	7	4,329,389	-
<b>Total assets</b>		<b>4,329,389</b>	<b>-</b>
<b>Equity and liabilities</b>			
<b>Equity</b>			
Stated capital	8	1,000	1,000
Accumulated loss		(21,315)	(24,873)
<b>Total equity</b>		<b>(20,315)</b>	<b>(23,873)</b>
<b>Liabilities</b>			
<b>Non-current liabilities</b>			
Loans from group companies	12	20,598	20,613
<b>Current liabilities</b>			
Provisions	9	18,260	3,260
Trade and other payables	10	4,312	-
Current tax liabilities	6	8,654	-
Loans from group companies	12	4,297,880	-
<b>Total current liabilities</b>		<b>4,329,106</b>	<b>3,260</b>
<b>Total liabilities</b>		<b>4,349,704</b>	<b>23,873</b>
<b>Total equity and liabilities</b>		<b>4,329,389</b>	<b>-</b>

# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Financial Statements for the year ended 31 March 2018

## Statement of Profit or Loss and Other Comprehensive Income

Figures in R

	Notes	2018	2017
Revenue	13	3,797,710	-
Cost of sales	14	(3,770,483)	-
<b>Gross profit</b>		<b>27,227</b>	<b>-</b>
Administrative expenses	15	(15,000)	(1,080)
Other losses	16	(15)	-
<b>Profit / (loss) from operating activities</b>		<b>12,212</b>	<b>(1,080)</b>
<b>Profit / (loss) before tax</b>		<b>12,212</b>	<b>(1,080)</b>
Income tax expense	17	(8,654)	-
<b>Profit / (loss) for the year</b>		<b>3,558</b>	<b>(1,080)</b>

# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Financial Statements for the year ended 31 March 2018

## Statement of Changes in Equity

Figures in R

	Stated capital	Accumulated loss	Total
<b>Balance at 1 March 2016</b>	1,000	(23,793)	(22,793)
<b>Changes in equity</b>			
Loss for the period	-	(1,080)	(1,080)
Total comprehensive income	-	(1,080)	(1,080)
<b>Balance at 31 March 2017</b>	<b>1,000</b>	<b>(24,873)</b>	<b>(23,873)</b>
<b>Balance at 1 April 2017</b>	1,000	(24,873)	(23,873)
<b>Changes in equity</b>			
Profit for the period	-	3,558	3,558
Total comprehensive income	-	3,558	3,558
<b>Balance at 31 March 2018</b>	<b>1,000</b>	<b>(21,315)</b>	<b>(20,315)</b>

Note **8**

# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Financial Statements for the year ended 31 March 2018

## Accounting Policies

---

### 1. Basis of preparation

The financial statements of Sun Pharmaceuticals (SA) (Pty) Ltd have been prepared in accordance with International Financial Reporting Standards and the Companies Act of South Africa. The financial statements have been prepared under the historical cost convention, as modified by the revaluation of land and buildings, available-for-sale financial assets, and financial assets and financial liabilities (including derivative instruments) at fair value through profit or loss.

The preparation of financial statements in conformity with International Financial Reporting Standards requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the company's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in note 3.

### 2. Summary of significant accounting policies

The principal accounting policies applied in the preparation of these annual financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

#### 2.1 Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

A financial asset is any asset that is:

- cash;
- an equity instrument of another entity;
- a contractual right to receive cash or another financial asset from another entity or to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity.
- a contract that will or may be settled in the entity's own equity instruments and is a non-derivative for which the entity is or may be obliged to receive a variable number of the entity's own equity instruments or
- a derivative that will or may be settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity's own equity instruments. For this purpose the entity's own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A and 16B, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C and 16D, or instruments that are contracts for the future receipt or delivery of the entity's own equity instruments.

# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Financial Statements for the year ended 31 March 2018

## Accounting Policies

---

A financial liability is any liability that is:

- a contractual obligation to deliver cash or another financial asset to another entity to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity.
- a contract that will or may be settled in the entity's own equity instruments and is a non-derivative for which the entity is or may be obliged to deliver a variable number of the entity's own equity instruments or a derivative that will or may be settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity's own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity's own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for these purposes the entity's own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A and 16B, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C and 16D, or instruments that are contracts for the future receipt or delivery of the entity's own equity instruments.

As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions.

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities.

A derivative is a financial instrument or other contract with all three of the following characteristics:

- its value changes in response to the change in a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract (sometimes called the 'underlying').
- it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and
- it is settled at a future date.

A financial asset or financial liability at fair value through profit or loss is a financial asset or financial liability that meets any of the following conditions.

- It is classified as held for trading. A financial asset or financial liability is classified as held for trading if it is acquired or incurred principally for the purpose of selling or repurchasing it in the near term, on initial recognition it is part of a portfolio of identified financial instruments that are managed together and for which there is evidence of a recent actual pattern of short-term profit-taking or it is a derivative (except for a derivative that is a financial guarantee contract or a designated and effective hedging instrument).
- It is contingent consideration of an acquirer in a business combination to which IFRS 3 Business Combinations applies.
- Upon initial recognition it is designated by the entity as at fair value through profit or loss.

Held-to-maturity investments are non-derivative financial assets with fixed or determinable payments and fixed maturity that an entity has the positive intention and ability to hold to maturity other than:

- those that the entity upon initial recognition designates as at fair value through profit or loss;
- those that the entity designates as available for sale; and
- those that meet the definition of loans and receivables.

# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Financial Statements for the year ended 31 March 2018

## Accounting Policies

---

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market other than:

- those that the entity intends to sell immediately or in the near term, which shall be classified as held for trading, and those that the entity upon initial recognition designates as at fair value through profit or loss;
- those that the entity upon initial recognition designates as available for sale; or
- those for which the holder may not recover substantially all of its initial investment, other than because of credit deterioration, which shall be classified as available for sale.

Available-for-sale financial assets are those non-derivative financial assets that are designated as available for sale or are not classified as (a) loans and receivables, (b) held-to-maturity investments or (c) financial assets at fair value through profit or loss.

### Classification and initial recognition

The company classifies financial assets and financial liabilities into the following categories:

- Financial assets at fair value through profit or loss - held for trading
- Financial assets at fair value through profit or loss - designated
- Held-to-maturity investment
- Loans and receivables
- Available-for-sale financial assets
- Financial liabilities at fair value through profit or loss - held for trading
- Financial liabilities at fair value through profit or loss - designated
- Financial liabilities measured at amortised cost.

Financial instruments are recognised initially when the company becomes a party to the contractual provisions of the instruments.

Classification of a financial instrument, or its component parts takes place on initial recognition. Each instrument is classified as a financial liability, a financial asset or an equity instrument in accordance with the substance of the contractual arrangement and the definitions of a financial liability, a financial asset and an equity instrument.

A financial asset classified as available-for-sale that would have met the definition of loans and receivables may be reclassified to loans and receivables if the entity has the intention and ability to hold the asset for the foreseeable future or until maturity. Financial instruments are not reclassified into the fair value through profit or loss category after initial recognition.

### Initial measurement

When a financial asset or financial liability is recognised initially, it is measured at its fair value plus, in the case of a financial asset or financial liability not at fair value through profit or loss, transaction costs that are directly attributable to the acquisition or issue of the financial asset or financial liability.

### Subsequent measurement

#### *Financial assets*

After initial recognition financial assets, including derivatives that are assets, are measured at their fair values, without any deduction for transaction costs which may be incurred on sale or other disposal, except for the following financial assets:

- loans and receivables are measured at amortised cost using the effective interest method
- held-to-maturity investments are measured at amortised cost using the effective interest method
- investments in equity instruments that do not have a quoted price in an active market and whose fair value cannot be reliably measured and derivatives that are linked to and must be settled by delivery of such equity instruments are measured at cost.

# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Financial Statements for the year ended 31 March 2018

## Accounting Policies

---

### *Financial liabilities*

After initial recognition, all financial liabilities are measured at amortised cost using the effective interest method, except for the following:

- financial liabilities at fair value through profit or loss, including derivatives that are liabilities, are measured at fair value except for a derivative liability that is linked to and must be settled by delivery of an equity instrument that does not have a quoted price in an active market for an identical instrument whose fair value cannot otherwise be reliably measured, is measured at cost
- financial liabilities that arise when a transfer of a financial asset does not qualify for derecognition or when the continuing involvement approach applies
- financial guarantee contracts are measured at the higher of the amount determined in accordance with IAS 37 and the amount initially recognised less, when appropriate, cumulative amortisation recognised
- commitments to provide a loan at a below-market interest rate is measured at the higher of the amount determined in accordance with IAS 37 and the amount initially recognised less, when appropriate, cumulative amortisation recognised

### **Offsetting financial instruments**

Financial assets and liabilities are offset and the net amount reported in the statement of financial position when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the company or the counterparty.

### **Derecognition**

Financial assets are derecognised when the contractual rights to the cash flows from the financial asset expire or when it is transferred and the transfer qualifies for derecognition.

### **Impairment of financial assets**

At the end of each reporting period an assessment is made to determine whether there is any objective evidence that a financial asset or group of financial assets is impaired. If any such evidence exists, the extent of the impairment is determined.

Impairment losses in financial assets carried at amortised cost are recognised in profit or loss.

Impairment losses are reversed when an increase in the financial asset's recoverable amount can be related objectively to an event occurring after the impairment was recognised, subject to the restriction that the carrying amount of the financial asset at the date that the impairment is reversed shall not exceed what the carrying amount would have been had the impairment not been recognised.

Reversals of impairment losses are recognised in profit or loss except for equity investments classified as available-for-sale.

### **Loans to (from) group companies**

These include loans to and from holding companies, fellow subsidiaries, subsidiaries, joint ventures and associates and are recognised initially at fair value plus direct transaction costs.

Loans to group companies are classified as loans and receivables and are measured at amortised cost using the effective interest method.

Loans from group companies are classified as financial liabilities at amortised cost and are measured at amortised cost using the effective interest method.

# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Financial Statements for the year ended 31 March 2018

## Accounting Policies

---

### Trade and other receivables

Trade receivables classified as loans and receivables are measured at initial recognition at fair value, and are subsequently measured at amortised cost using the effective interest rate method. Appropriate allowances for estimated irrecoverable amounts are recognised in profit or loss when there is objective evidence that the asset is impaired. Significant financial difficulties of the debtor, probability that the debtor will enter bankruptcy or financial reorganisation, and default or delinquency in payments (more than 30 days overdue) are considered indicators that the trade receivable is impaired. The allowance recognised is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows discounted at the effective interest rate computed at initial recognition.

The carrying amount of the asset is reduced through the use of an allowance account, and the amount of the loss is recognised in profit or loss within operating expenses. When a trade receivable is uncollectable, it is written off against the allowance account for trade receivables. Subsequent recoveries of amounts previously written off are credited against operating expenses in profit or loss.

Trade and other receivables are classified as loans and receivables.

### Trade and other payables

Trade payables are initially measured at fair value, and are subsequently measured at amortised cost, using the effective interest rate method.

## 2.2 Provisions and contingencies

A provision is a liability of uncertain timing or amount. A liability is a present obligation of the entity arising from past events, the settlement of which is expected to result in an outflow from the entity of resources embodying economic benefits.

A contingent liability is:

- a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity; or
- a present obligation that arises from past events but is not recognised because it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation or the amount of the obligation cannot be measured with sufficient reliability.

A contingent asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity.

A provision is recognised when:

- there is a present obligation (legal or constructive) as a result of a past event
- it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and
- a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period. Where the effect of the time value of money is material, the amount of a provision is the present value of the expenditures expected to be required to settle the obligation.

Where some or all of the expenditure required to settle a provision is expected to be reimbursed by another party, the reimbursement is recognised when it is virtually certain that reimbursement will be received when the obligation is settled. The reimbursement is treated as a separate asset. The amount recognised for the reimbursement will not exceed the amount of the provision.



# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Financial Statements for the year ended 31 March 2018

## Accounting Policies

---

Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate. If it is no longer probable that an outflow of resources embodying economic benefits will be required to settle the obligation, the provision is reversed.

A provision is used only for expenditures for which the provision was originally recognised.

Provisions are not recognised for future operating losses.

The present obligation under an onerous contract is recognised and measured as a provision.

A constructive obligation to restructure arises only when:

- there is a detailed formal plan for the restructuring identifying at least the business or part of a business concerned, the principal locations affected, the location, function, and approximate number of employees who will be compensated for terminating their services, the expenditures that will be undertaken and when the plan will be implemented; and
- there has been raised a valid expectation in those affected that the restructuring will be carried out by starting to implement that plan or announcing its main features to those affected by it.

After initial recognition and until the liability is settled, cancelled or expires, a contingent liability is recognised in a business combination at the higher of the amount that would be recognised as a provision, and the amount initially recognised less cumulative amortisation.

Contingent assets and liabilities are not recognised, but details are disclosed in the notes to the annual financial statements.

## 2.3 Revenue

Revenue is the gross inflow of economic benefits during the period arising in the course of the ordinary activities where those inflows result in increases in equity, other than increases relating to contributions from equity participants.

Revenue is measured at the fair value of the consideration received or receivable. Revenue is shown net of value-added tax, returns, rebates and discounts.

Revenue from the sale of goods is recognised when:

- significant risks and rewards of ownership of the goods have been transferred to the buyer;
- the entity retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- the amount of revenue can be measured reliably;
- it is probable that the economic benefits associated with the transaction will flow to the entity; and
- the costs incurred or to be incurred in respect of the transaction can be measured reliably.

When the outcome of a transaction involving the rendering of services can be estimated reliably, revenue associated with the transaction is recognised by reference to the stage of completion of the transaction at the end of the reporting period. The outcome of a transaction can be estimated reliably when all the following conditions are satisfied:

- the amount of revenue can be measured reliably;
- it is probable that the economic benefits associated with the transaction will flow to the entity; and
- the stage of completion of the transaction at the end of the reporting period can be measured reliably; and
- the costs incurred for the transaction and the costs to complete the transaction can be measured reliably.

# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Financial Statements for the year ended 31 March 2018

## Accounting Policies

---

When the outcome of transactions involving the rendering of services cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that are recoverable.

The stage of completion of a transaction may be determined by a variety of methods, depending on the nature of the transaction:

- surveys of work performed;
- services performed to date as a percentage of total services to be performed;
- the proportion that costs incurred to date bear to the estimated total costs of the transaction. Only costs that reflect services performed to date are included in costs incurred to date. Only costs that reflect services performed or to be performed are included in the estimated total costs of the transaction.

Progress payments and advances received from customers often do not reflect the services performed.

Interest income is recognised using the effective interest method.

Rental income from investment property that is leased to a third party under an operating lease is recognised in the statement of comprehensive income on a straight-line basis over the lease term and is included in 'other income'.

Dividend income from associates is recognised when the company's right to receive payment has been established and is shown as 'other income'.

Royalties are recognised on an accrual basis in accordance with the substance of the relevant agreement.

## 2.4 Related parties

A related party is a person or entity that is related to the entity that is preparing its financial statements (in this Standard referred to as the 'reporting entity').

- A person or a close member of that person's family is related to a reporting entity if that person:
  - has control or joint control of the reporting entity;
  - has significant influence over the reporting entity; or
  - is a member of the key management personnel of the reporting entity or of a parent of the reporting entity.
- An entity is related to a reporting entity if any of the following conditions applies:
  - The entity and the reporting entity are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others).
  - One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member).
  - Both entities are joint ventures of the same third party.
  - One entity is a joint venture of a third entity and the other entity is an associate of the third entity.
  - The entity is a post-employment benefit plan for the benefit of employees of either the reporting entity or an entity related to the reporting entity. If the reporting entity is itself such a plan, the sponsoring employers are also related to the reporting entity.
  - The entity is controlled or jointly controlled by a person identified as a related party.
  - A person identified as having control or joint control over the reporting entity has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity).
  - The entity, or any member of a group of which it is a part, provides key management personnel services to the reporting entity or to the parent of the reporting entity.

# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Financial Statements for the year ended 31 March 2018

## Accounting Policies

---

### 3. Critical accounting estimates and judgements

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

#### 3.1 Critical accounting estimates and assumptions

The company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are addressed below.

##### 3.1.1 Income taxes

The company is subject to income taxes in numerous jurisdictions. Significant judgement is required in determining the worldwide provision for income taxes. There are many transactions and calculations for which the ultimate tax determination is uncertain. The company recognises liabilities for anticipated tax audit issues based on estimates of whether additional taxes will be due. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the current and deferred income tax assets and liabilities in the period in which such determination is made.

### 4. Changes in accounting policies and disclosures

#### 4.1 Adoption of new and revised pronouncements

In the current year, the company has adopted all new and revised IFRSs that are relevant to its operations and effective for annual reporting periods beginning on or after 1 April 2017.

At the date of authorisation of these financial statements for the year ended 31 March 2018, the following IFRSs were adopted:

##### Disclosure Initiative (Amendments to IAS 1)

Amends IAS 1 Presentation of Financial Statements to address perceived impediments to preparers exercising their judgement in presenting their financial reports by making the following changes:

- clarification that information should not be obscured by aggregating or by providing immaterial information, materiality considerations apply to the all parts of the financial statements, and even when a standard requires a specific disclosure, materiality considerations do apply;
- clarification that the list of line items to be presented in these statements can be disaggregated and aggregated as relevant and additional guidance on subtotals in these statements and clarification that an entity's share of OCI of equity-accounted associates and joint ventures should be presented in aggregate as single line items based on whether or not it will subsequently be reclassified to profit or loss;
- additional examples of possible ways of ordering the notes to clarify that understandability and comparability should be considered when determining the order of the notes and to demonstrate that the notes need not be presented in the order so far listed in paragraph 114 of IAS 1.

# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Financial Statements for the year ended 31 March 2018

## Accounting Policies

---

### Recognition of Deferred Tax Assets for Unrealised Losses (Amendments to IAS 12)

Amends IAS 12 Income Taxes to clarify the following aspects:

- Unrealised losses on debt instruments measured at fair value and measured at cost for tax purposes give rise to a deductible temporary difference regardless of whether the debt instrument's holder expects to recover the carrying amount of the debt instrument by sale or by use.
- The carrying amount of an asset does not limit the estimation of probable future taxable profits.
- Estimates for future taxable profits exclude tax deductions resulting from the reversal of deductible temporary differences.
- An entity assesses a deferred tax asset in combination with other deferred tax assets. Where tax law restricts the utilisation of tax losses, an entity would assess a deferred tax asset in combination with other deferred tax assets of the same type.

Application of the above standards did not impact these financial statements.

### 4.2 New standards and interpretations not yet adopted

The company has not applied the following new, revised or amended pronouncements that have been issued by the IASB as they are not yet effective for the annual financial year beginning 1 April 2017 (the list does not include information about new requirements that affect interim financial reporting or first-time adopters of IFRS since they are not relevant to the company). The directors anticipate that the new standards, amendments and interpretations will be adopted in the company's financial statements when they become effective. The company has assessed, where practicable, the potential impact of all these new standards, amendments and interpretations that will be effective in future periods.

#### IFRS 9 Financial Instruments (2014)

A finalised version of IFRS 9 which contains accounting requirements for financial instruments, replacing IAS 39 Financial Instruments: Recognition and Measurement. The standard contains requirements in the following areas:

- Classification and measurement. Financial assets are classified by reference to the business model within which they are held and their contractual cash flow characteristics. The 2014 version of IFRS 9 introduces a 'fair value through other comprehensive income' category for certain debt instruments. Financial liabilities are classified in a similar manner to under IAS 39, however there are differences in the requirements applying to the measurement of an entity's own credit risk.
- Impairment. The 2014 version of IFRS 9 introduces an 'expected credit loss' model for the measurement of the impairment of financial assets, so it is no longer necessary for a credit event to have occurred before a credit loss is recognised.
- Hedge accounting. Introduces a new hedge accounting model that is designed to be more closely aligned with how entities undertake risk management activities when hedging financial and non-financial risk exposures
- Derecognition. The requirements for the derecognition of financial assets and liabilities are carried forward from IAS 39.

It is unlikely that the amendment will have a material impact on the company's annual financial statements.

The mandatory implementation required by the standard is for years ending on or after 1 January 2018. This change in accounting policy will be implemented for the first time for the financial year ending 31 March 2019.

#### IFRS 15 Revenue from Contracts with Customers

IFRS 15 provides a single, principles based five-step model to be applied to all contracts with customers.

# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Financial Statements for the year ended 31 March 2018

## Accounting Policies

---

The five steps in the model are as follows:

- Identify the contract with the customer
- Identify the performance obligations in the contract
- Determine the transaction price
- Allocate the transaction price to the performance obligations in the contracts
- Recognise revenue when (or as) the entity satisfies a performance obligation.

Guidance is provided on topics such as the point in which revenue is recognised, accounting for variable consideration, costs of fulfilling and obtaining a contract and various related matters. New disclosures about revenue are also introduced.

It is unlikely that the amendment will have a material impact on the company's annual financial statements.

The mandatory implementation required by the standard is for years ending on or after 1 January 2018. This change in accounting policy will be implemented for the first time for the financial year ending 31 March 2019.

### IFRIC 22 Foreign Currency Transactions and Advance Consideration

The interpretation addresses foreign currency transactions or parts of transactions where:

- there is consideration that is denominated or priced in a foreign currency;
- the entity recognises a prepayment asset or a deferred income liability in respect of that consideration, in advance of the recognition of the related asset, expense or income; and
- the prepayment asset or deferred income liability is non-monetary.

The Interpretations Committee came to the following conclusion:

- The date of the transaction, for the purpose of determining the exchange rate, is the date of initial recognition of the non-monetary prepayment asset or deferred income liability.
- If there are multiple payments or receipts in advance, a date of transaction is established for each payment or receipt.

It is unlikely that the amendment will have a material impact on the company's annual financial statements.

The mandatory implementation required by the standard is for years ending on or after 1 January 2018. This change in accounting policy will be implemented for the first time for the financial year ending 31 March 2019.

### IFRIC 23 Uncertainty over Income Tax Treatments

The interpretation addresses the determination of taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates, when there is uncertainty over income tax treatments under IAS 12. It specifically considers:

- whether tax treatments should be considered collectively
- assumptions for taxation authorities' examinations
- the determination of taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates
- the effect of changes in facts and circumstances

It is unlikely that the amendment will have a material impact on the company's annual financial statements.

The mandatory implementation required by the standard is for years ending on or after 1 January 2019. This change in accounting policy will be implemented for the first time for the financial year ending 31 March 2020.

# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Financial Statements for the year ended 31 March 2018

## Accounting Policies

---

### Annual Improvements to IFRS Standards 2015–2017 Cycle

Makes amendments to the following standards:

- IFRS 3 and IFRS 11 - The amendments to IFRS 3 clarify that when an entity obtains control of a business that is a joint operation, it remeasures previously held interests in that business. The amendments to IFRS 11 clarify that when an entity obtains joint control of a business that is a joint operation, the entity does not remeasure previously held interests in that business.
- IAS 12 - The amendments clarify that all income tax consequences of dividends (i.e. distribution of profits) should be recognised in profit or loss, regardless of how the tax arises.
- IAS 23 - The amendments clarify that if any specific borrowing remains outstanding after the related asset is ready for its intended use or sale, that borrowing becomes part of the funds that an entity borrows generally when calculating the capitalisation rate on general borrowings.

It is unlikely that the amendment will have a material impact on the company's annual financial statements.

The mandatory implementation required by the standard is for years ending on or after 1 January 2019. This change in accounting policy will be implemented for the first time for the financial year ending 31 March 2020.

# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Financial Statements for the year ended 31 March 2018

## Notes to the Financial Statements

Figures in R

2018

2017

### 5. Financial assets

#### 5.1 Carrying amount of financial assets by category

	<b>Loans and receivables</b>	<b>Total</b>
<b>Year ended 31 March 2018</b>		
Loan to group company (Note 7)	4,329,389	4,329,389

### 6. Current tax liabilities

#### 6.1 Current tax liabilities comprise the following balances

Net current tax liability from all items being set off	(8,654)	-
Total current tax liability as per the statement of financial position	(8,654)	-

### 7. Loan to group company

#### 7.1 Loan to group company comprise the following balances

Ranbaxy Pharmaceuticals (Pty) Ltd	4,329,389	-
The loan is unsecured, interest free and has no fixed terms of repayment		

### 8. Stated capital

#### 8.1 Authorised and issued share capital

<b>Authorised</b>		
1000 Ordinary shares of non par value	1,000	1,000
<b>Issued</b>		
1000 Ordinary shares of non par value	1,000	1,000

### 9. Provisions

#### 9.1 Provisions are made up as follows:

Provision for audit fees	18,260	3,260
--------------------------	--------	-------

# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Financial Statements for the year ended 31 March 2018

## Notes to the Financial Statements

Figures in R

2018

2017

### 10. Trade and other payables

#### 10.1 Trade and other payables are made up as follows:

Value added tax	4,312	-
<b>Total trade and other payables</b>	<b>4,312</b>	<b>-</b>

### 11. Financial liabilities

#### 11.1 Carrying amount of other financial liabilities by category

	<u>At amortised cost</u>	<u>Total</u>
<b>Year ended 31 March 2018</b>		
Loans from group companies (Note 12)	<u>4,318,478</u>	<u>4,318,478</u>

### 12. Loan to group company

#### 12.1 Loan to group company are analysed as follows:

Sun Pharma Global FZE	20,598	20,613
Sun Pharma Industries Limited	3,728,744	-
Ranbaxy Pharmaceuticals (Pty) Ltd	569,136	-
The loan is unsecured, interest free and has no fixed terms of repayment		
	<u>4,318,478</u>	<u>20,613</u>
Non-current liabilities	20,598	20,613
Current liabilities	4,297,880	-
	<u>4,318,478</u>	<u>20,613</u>

### 13. Revenue

#### 13.1 Revenue comprises

Sale of goods	<u>3,797,710</u>	<u>-</u>
---------------	------------------	----------

### 14. Cost of sales

#### 14.1 Cost of sales is analysed as follows:

Sale of goods	<u>3,770,483</u>	<u>-</u>
---------------	------------------	----------



# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Financial Statements for the year ended 31 March 2018

## Notes to the Financial Statements

Figures in R

2018

2017

<b>15. Administrative expenses</b>		
<b>15.1 Administrative expenses consist:</b>		
Auditors remuneration - fees	15,000	1,080
<b>16. Other gains and losses</b>		
<b>16.1 Other gains and losses consist:</b>		
Foreign Exchange fluctuation (Loss)/Profit	(15)	-
<b>17. Income tax expense</b>		
<b>17.1 Income tax recognised in profit or loss:</b>		
<b>Current tax</b>		
Current year	(8,654)	-
	<b>(8,654)</b>	-
Total income tax expense	<b>(8,654)</b>	-

# Sun Pharmaceuticals (SA) (Pty) Ltd

(Registration Number 2008/025010/07)

Financial Statements for the year ended 31 March 2018

## Notes to the Financial Statements

Figures in R

2018

2017

### 18. Related parties

#### 18.1 Group companies

Parent company	Sun Pharma (Netherlands) BV incorporated in Netherlands
Ultimate parent	Sun Pharmaceuticals Industries Limited incorporated in India
Sister Company	Sun Pharma Global FZE
Sister Company	Ranbaxy Pharmaceuticals (Pty) Ltd

#### 18.2 Related party transactions and balances

	Parent	Sun Pharma Global FZE	Ranbaxy Pharmaceuti cals (Pty) Ltd	Total
<b>Year ended 31 March 2018</b>				
<b>Related party transactions</b>				
Purchases of goods	3,728,744	-	569,136	4,297,880
<b>Outstanding balances for related party transactions</b>				
Amounts payable	(3,728,744)	-	(569,136)	(4,297,880)
<b>Outstanding loan accounts</b>				
Amounts payable	-	(20,598)	-	(20,598)
<b>Year ended 31 March 2017</b>				
<b>Outstanding loan accounts</b>				
Amounts payable	-	(20,613)	-	(20,613)

### 19. Financial risk management

#### 19.1 Market Risk

##### 19.1.1 Foreign exchange risk

The group operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the US dollar. Foreign exchange risk arises when future commercial transactions, recognised assets and liabilities are denominated in a currency that is not the entity's functional currency.

#### 19.2 Liquidity risk

Cash flow forecasting is performed in the operating entities of the company in and aggregated by company finance. Company finance monitors rolling forecasts of the company's liquidity requirements to ensure it has sufficient cash to meet operational needs.